Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma|
- Safety profile of treatment, characterisation of adverse events
- Efficacy - clinical response of injected and non-injected tumours
|Study Start Date:||August 2005|
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.
|Australia, New South Wales|
|Melanoma Unit, Mater Misericordiae Hospital|
|Newcastle, New South Wales, Australia, 2298|
|Principal Investigator:||Peter Hersey, MBBS, DPhil||Conjoint Professor, Newcastle Mater Misericordiae Hopital|